Previous close | 41.90 |
Open | 41.90 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 41.90 - 41.90 |
52-week range | 34.33 - 49.86 |
Volume | |
Avg. volume | 119 |
Market cap | 12.294B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 23.54 |
EPS (TTM) | 1.78 |
Earnings date | 30 Jul 2024 |
Forward dividend & yield | 1.28 (3.06%) |
Ex-dividend date | 17 May 2024 |
1y target est | N/A |
German healthcare group Fresenius first-quarter results beat expectations, the company said on Wednesday, citing strong performance at its Kabi and Helios businesses, prompting it to raise its full-year outlook. First-quarter earnings before interest and tax (EBIT) were 633 million euros ($680 million), above analysts' expectations of 606 million euros, according to a consensus of forecasts from Vara Research. In a bid to get leaner, Fresenius also said that it would sell its investment unit, Fresenius Vamed, completing its portfolio restructuring.
Fresenius Medical Care ( ETR:FME ) First Quarter 2024 Results Key Financial Results Revenue: €4.73b (flat on 1Q 2023...
Helen Giza, Chief Executive Officer of Fresenius Medical Care, said: